Abstract Number: 1749 • 2018 ACR/ARHP Annual Meeting
Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis
Background/Purpose: Patients with pulmonary-renal or renal-limited microscopic polyangiitis (MPA) frequently manifested with rapidly progressive glomerular nephritis resulting in chronic renal failure if clinical response to…Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…Abstract Number: 2015 • 2018 ACR/ARHP Annual Meeting
Association of Anti-Ro52 Autoantibodies with Interstitial Lung Disease and More Severe Disease Manifestations in Juvenile Idiopathic Inflammatory Myopathies
Background/Purpose: Myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA) found in adult and juvenile idiopathic inflammatory myopathies (JIIM) often confer a specific disease phenotype.…Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…Abstract Number: 2675 • 2017 ACR/ARHP Annual Meeting
Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease once characterized by high mortality rates now with better outcomes. Pulmonary disease has overtaken renal failure…Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…Abstract Number: 1333 • 2017 ACR/ARHP Annual Meeting
Mortality of Tumor Necrosis Factor Transgenic Arthritic Mice with Interstitial Lung Disease Occurs with Pulmonary Arteriole Thickening and Right Ventricular Hypertrophy but Is Not Associated with Inducible Nitric Oxide Synthase Dependent Inflammatory Cell Infiltration
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) occurs in up to 15% of RA patients, whose median survival expectancy after diagnosis is only 2.6…Abstract Number: 1684 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
Background/Purpose: Systemic sclerosis (SSc) is the disease characterized by organ fibrosis with unknown etiology, and pulmonary involvement is one of major cause of death. However,…Abstract Number: 1695 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is a major contributor to morbidity and mortality in systemic sclerosis (SSc). We sought to identify the distribution of clinical…Abstract Number: 1702 • 2017 ACR/ARHP Annual Meeting
Disease Progression in Systemic Sclerosis Patients with Concomittant or Isolated Interstitial Lung Disease and Pulmonary Arterial Hypertension in the Scleroderma Cohort Singapore
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are leading causes of mortality in patients with systemic sclerosis (SSc). We aimed to determine…Abstract Number: 2008 • 2017 ACR/ARHP Annual Meeting
“Intrathoracic Manifestations of Connective Tissue Diseases on High Resolution Computed Tomography”
Background/Purpose: Connective tissue diseases (CTD) can cause intrathoracic involvement, increasing patients morbidity and mortality. High-resolution computed tomography (HRCT) is a key method for evaluation of…Abstract Number: 2114 • 2017 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?
- Background/Purpose: Interstitial lung disease (ILD) can be an early manifestation of an occult connective tissue disease (CTD). It is important to separate these patients…Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting
Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 18
- Next Page »